Background. It has been shown that in the pre-COVID period, the number of children with acute respiratory viral infection (ARVI) was annually recorded at about 80–120 thousand diseases per 100 thousand of the pediatric population (3.3 times higher than in adults) without a downward trend. At the same time, the incidence of previously registered, but disappeared during the COVID-19 pandemic, influenza in children was previously 1.9–2.8 times higher than in the general population. According to the WHO National Center for Influenza, influenza viruses will reappear in circulation in Russia by 48–49 weeks 2021, predicting an epidemic rise of this disease along with COVID.
Objective. Summary of the results of monitoring of the therapeutic efficacy of the neuraminidase inhibitor oseltamivir in influenza in children aged 1 year or older.
Methods. 434 children aged from 1 to 17 years were followed-up for the study of the therapeutic efficacy of oseltamivir in patients with influenza and acute respiratory viral infections. The etiology of ARVI was established by detecting pathogen antigens in the material from the nasal passages and nasopharynx of patients by polymerase chain reaction or immunofluorescence express method.
Results. The inclusion of the drug in the early stages of the disease in the treatment of influenza contributed to a more rapid elimination of the main symptoms of the disease (fever, intoxication, signs of catarrh in the nasopharynx and larynx in children aged 1 year or older) and a reduction in the duration of influenza virus isolation in these organs. An increase in the effectiveness of the drug when combined with intranasal administration of recombinant interferon α2b has been proven.

Keywords: oseltamivir, interferon α2b, children 1 year and older, ARVI, influenza